Last reviewed · How we verify
SARS-CoV-2 rS - Phase 1
At a glance
| Generic name | SARS-CoV-2 rS - Phase 1 |
|---|---|
| Sponsor | Novavax |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of NVX-CoV2705 (PHASE3)
- Efficacy and Safety of NVX-CoV2705 (PHASE4)
- A Strain Change Study for SARS-CoV-2 rS Vaccines (PHASE3)
- Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines (PHASE3)
- A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom (PHASE3)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine (PHASE1, PHASE2)
- Lot Consistency Study of COVID-19 and Influenza Combination Vaccine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 rS - Phase 1 CI brief — competitive landscape report
- SARS-CoV-2 rS - Phase 1 updates RSS · CI watch RSS
- Novavax portfolio CI